Ready-to-Use Solutions Speed Up MAb Bioprocessing

摘要

The biopharmaceutical industry constantly strives to increase project throughput and flexibility of operations, enabling shorter time to clinic. The adoption of single-use and ready-to-use technologies has proved helpful by lowering capital expenditure and maintenance cost, reducing commissioning time, and providing an efficient means to work with higher project throughput. The technologies available can help reduce down time in a facility and ensure more flexible operations. Working with single-useand ready-to-use equipment eliminates several process steps and cuts process time. GE Healthcare offers a range of ready-to-use products in the ReadyTo Process platform that are designed to speed up the manufacturing of monoclonal antibodies (MAbs).